Market Movers (8-K)
NASDAQ
Avalyn Pharma announced second quarter 2026 financial results, highlighting the completion of enrollment for its MIST Phase 2b trial of AP01 and a cash runway projected into 2029.
Capital raise
NASDAQ
Avalyn Pharma Inc. has amended its sublease agreement to expand its office space in Boston, Massachusetts, increasing its rentable square footage and future lease payments.
Quarterly Earnings (10-Q)
NASDAQ
Avalyn Pharma Inc. details progress in its Phase 2b clinical trial for AP01 and Phase 2 trial for AP02, alongside a robust cash position post-IPO, while acknowledging ongoing development risks.
Capital raise
Schedule 13G - Passive Investments
NASDAQ
Novo Holdings A/S has reported beneficial ownership of 3,883,289 shares, representing 8.8% of Avalyn Pharma Inc.'s common stock.
NASDAQ
Norwest Venture Partners XV, LP, along with affiliated entities and individuals, has reported a beneficial ownership of 5.1% of Avalyn Pharma Inc.'s common stock as of June 30, 2026.
NASDAQ
FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 13.2% of Avalyn Pharma Inc.'s common shares as of June 30, 2026.